Combination therapy for unresectable bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four treatments for people with bile duct cancer that cannot be removed by surgery. The treatments include chemotherapy directly into the liver, tiny beads with chemo, an immunotherapy drug, and a targeted therapy pill. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with bile duct cancer that has spread within the liver but not to other organs.
- Tumor is too large or located in a way that surgery is not possible.
- Never received immunotherapy or other systemic cancer treatments before.
- Liver function is good, with no or only mild fluid buildup in the belly.
- Overall health allows daily activities with minimal help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of treatments for people with bile duct or gallbladder cancer that cannot be removed by surgery. It uses a procedure to burn the tumor (radiofrequency ablation) along with two drugs: one that boosts your immune system and one that targets blood vessels feeding the cancer.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has worsened after one prior treatment. It may be an option if you haven't taken capecitabine or lenvatinib before and are generally feeling well.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.